Monoclonal antibodies

Monoclonal antibody
#Alligator Bioscience #Mergers and acquisitions #Monoclonal antibodies #Oncology

Alligator Bioscience sells CD40 agonist antibody to Biossil

Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil.   Alligator will receive $750,000 upfront and is eligible for up to $108 million in milestone payments, as well as royalties on future sales, capped at $250 million in total.  Under… Read More

#Business & Investment #Cancer Research #News

Monoclonal antibody
#Bionyra Pharma #Inflammatory Bowel Disease #Monoclonal antibodies #Phase I trial

Positive Phase I results for long-acting anti-TL1A antibody

Bionyra Pharma has announced positive interim results from its ongoing Phase I first-in-human study of BYN-002 (TL-001), a long-acting anti-TL1A monoclonal antibody that is in development to treat inflammatory bowel disease (IBD) and other TL1A-driven diseases.   The data are being presented in a late-breaking poster at United… Read More

#News

Johnson & Johnson head office
#Crohn's disease #Johnson & Johnson #Monoclonal antibodies #Phase III trial

J&J reports positive results for Tremfya

Johnson & Johnson has reported positive results for its Phase III FUZION study of its Tremfya (guselkumab) therapy for Crohn’s disease.   The findings show that Tremfya maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease. Johnson & Johnson state the findings, which are… Read More

#Editor's Choice #News

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced rectal cancer often receive chemotherapy… Read More

#Cancer Research #News #Regulatory #Trending News

Monoclonal antibodies
#Chronic obstructive pulmonary disease (COPD) #Connect Biopharma #Monoclonal antibodies #Phase II trial

Monoclonal antibody reduces COPD exacerbations in Phase II trial

Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody.  The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More

#News

Novartis
#Monoclonal antibodies #Neurodegenerative disorders #Novartis #Phase III trial

Novartis faces September’s fourth trial disappointment with ALS drug

Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases.  The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed.  VHB937… Read More

#News #Trending News

#Infex Therapeutics #Monoclonal antibodies #Phase II trial #Respiratory

New Phase IIa data for RESP-X revealed at ERS Congress 2026

Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa).  The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More

#News

Intestinal tract
#Coeliac disease #Monoclonal antibodies #Phase II trial #Teva

Positive results for anti-IL-15 monoclonal antibody in coeliac disease

Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease.   The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More

#News

Monoclonal antibodies
#Cushing's disease #Cushing’s syndrome #Monoclonal antibodies #Orphan designation

Orphan designation granted for Cushing’s syndrome mAb

The European Commission has granted orphan designation to asedebart (Lu AG13909) to brain health biopharmaceutical company Lundbeck’s novel investigational anti-ACTH monoclonal antibody (mAb), for the treatment of Cushing’s syndrome of endogenous origin.  Cushing’s syndrome of endogenous origin includes both ACTH-dependent and ACTH-independent forms. ACTH-dependent Cushing’s syndrome is a rare, serious endocrine… Read More

#News

Bispecific antibodies
#Bispecific Antibodies #Boulevard Bio #Fundraising #Monoclonal antibodies #Start-ups

Multi-specific antibody company launches with $65 million

Boulevard Bio has emerged from stealth with $65 million from founding investor Deerfield Management and early Phase I healthy volunteer data for lead candidate BLVD101.   Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), Boulevard's approach is grounded in a deep… Read More

#Business & Investment #News

Lung cancer
#Kairos Pharma #Lung cancer #Monoclonal antibodies #Oncology

New drug could change post-progression treatment of EGFR-NSCLC

Kairos Pharma has shared interim safety data from its ongoing Phase I clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca’s Tagrisso) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The company says the data represent a pivotal milestone in its lead programme: resensitising patients… Read More

#Cancer Research #News

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

Monoclonal antibody
#Lung disease #Monoclonal antibodies #University of Florida

Rare lung disease treated with monoclonal antibody

A proof-of-concept study led by a scientist at the University of Florida suggests a monoclonal antibody that targets a master regulator of inflammation, called NAMPT, could offer much-needed treatment for acute respiratory distress syndrome (ARDS).  In the study, a monoclonal antibody treatment called ALT-100 was used in… Read More

#News

Drugs targeting amyloid Plaque
#Alzheimer's #Monoclonal antibodies #Neurodegenerative disorders #Neuroscience

Refining, not abandoning, the amyloid hypothesis: Precision medicine after the Cochrane review 

Susan Abushakra, MD, Chief Medical Officer at Alzheon, discusses the validity of the amyloid hypothesis in light of the recent Cochrane review that found no clinical benefit of anti-amyloid monoclonal antibodies.  A Cochrane systematic review published in April 2026 by Nonino, et al. – examining 17 randomised controlled trials encompassing… Read More

#Exclusive Content

Blood cells
#Monoclonal antibodies #Phase II trial #Rare disease #Takeda

NEJM data support Takeda’s treatment for ITP

The New England Journal of Medicine (NEJM) has published final results from a Phase II study evaluating Takeda’s mezagitamab (TAK-079), an investigational treatment option for patients with primary immune thrombocytopenia (ITP).  The NEJM-published data showed patients treated with mezagitamab achieved:  … Read More

#News

Monoclonal antibodies
#iBio #Monoclonal antibodies #Phase I trial #Weight loss

iBio initiates Phase I trial for weight loss antibody

iBio has received approval to initiate a first-in-human clinical trial for its long-acting monoclonal antibody IBIO-600 in Australia.  The Phase I study is a randomised, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult… Read More

#News